#United States #New York #FDA #Pomerantz Law #PepGen

Pomerantz Law Firm Investigates PepGen Inc. Investors

In recent developments, the Pomerantz Law Firm has announced that it is launching an investigation concerning potential claims on behalf of investors in PepGen Inc. (NASDAQ: PEPG). This initiative arises following serious concerns related to the company's business practices and possible securities fraud.

Overview of the Investigation

The firm encourages investors who may have suffered losses to reach out for further information. Danielle Peyton, the lawyer overseeing the case, can be contacted at [email protected] or via phone at 646-581-9980, extension 7980. This investigation focuses on whether PepGen, alongside its officers or directors, might have engaged in unlawful activities that could have misled investors.

Recent Events Impacting PepGen Stock

On March 4, 2026, PepGen issued a press release stating that the U.S. Food and Drug Administration (FDA) had placed a partial clinical hold on its ongoing clinical trial, known as FREEDOM2-DM1. This study aims to assess the efficacy of PGN-EDODM1 in patients diagnosed with myotonic dystrophy type 1. The FDA's hold raises questions regarding previously submitted pharmacology and toxicology data, which had been a foundation for the trial.

As a direct consequence of this news, PepGen's stock price plummeted on March 5, 2026, decreasing by $1.25 per share or 18.57%, ultimately closing at $5.50. The implications of such a significant drop in stock price indicate heightened worry among investors regarding the company's stability and future.

Further compounding investor anxiety, the company released clinical data from the trial's 5 mg/kg cohort on March 30, 2026. Although PepGen framed the findings as promising, analysts highlighted a concerning lack of significant improvements in key metrics, such as patients' handgrip strength and performance in a 10-meter walk/run test. As a result of this disappointing data, PepGen's stock experienced a more severe decline of $2.46 per share, translating to a staggering 58.16% drop, closing at just $1.77 on March 31, 2026.

About Pomerantz LLP

Pomerantz LLP, recognized as a leading advocate for investors, especially in cases involving securities fraud, has a rich history that dates back more than 85 years. Founded by Abraham L. Pomerantz, the firm has established itself as a respected name in corporate, securities, and antitrust class litigation. Pomerantz has successfully secured substantial damages for numerous class members who have fallen victim to corporate misconduct.

Their commitment to defending the rights of investors remains strong, as they have continuously pursued cases that highlight fiduciary breaches and fraudulent activities within corporate frameworks.

Next Steps for Investors

For investors who have been affected by the recent actions taken by PepGen or the market reactions to them, reaching out to Pomerantz LLP represents a proactive step to explore potential recourse. Investor protection remains a top priority, and those seeking to navigate their options amid the uncertainty of this situation are encouraged to engage the firm for support.

In conclusion, the ongoing investigation by Pomerantz LLP serves as a critical reminder of the potential volatility in the biopharmaceutical sector. It underscores the need for vigilance among investors, especially in light of regulatory scrutiny and the inherent risks associated with clinical trials.